BioCryst Pharmaceuticals Ownership
| BCRX Stock | USD 8.31 0.23 2.69% |
Shares in Circulation | First Issued 1994-03-31 | Previous Quarter 206.9 M | Current Value 206.7 M | Avarage Shares Outstanding 63.7 M | Quarterly Volatility 60.7 M |
BioCryst |
BioCryst Stock Ownership Analysis
About 81.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.43. BioCryst Pharmaceuticals had not issued any dividends in recent years. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. For more info on BioCryst Pharmaceuticals please contact Jon Stonehouse at 919 859 1302 or go to https://www.biocryst.com.BioCryst Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioCryst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioCryst Pharmaceuticals backward and forwards among themselves. BioCryst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase BioCryst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caligan Partners Lp | 2024-12-31 | 3 M | Gw&k Investment Management, Llc | 2024-12-31 | 2.9 M | Rock Springs Capital Management Lp | 2024-12-31 | 2.7 M | Two Sigma Advisers, Llc | 2024-12-31 | 2.5 M | Rice Hall James & Associates, Llc | 2024-12-31 | 2.1 M | Northern Trust Corp | 2024-12-31 | 2 M | Eversept Partners, Llc | 2024-12-31 | 2 M | Charles Schwab Investment Management Inc | 2024-12-31 | 2 M | Stifel Financial Corp | 2024-12-31 | 1.8 M | Blackrock Inc | 2024-12-31 | 22.1 M | Vanguard Group Inc | 2024-12-31 | 21.9 M |
BioCryst Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioCryst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioCryst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioCryst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioCryst Pharmaceuticals Outstanding Bonds
BioCryst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioCryst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioCryst bonds can be classified according to their maturity, which is the date when BioCryst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View |
BioCryst Pharmaceuticals Corporate Filings
8K | 4th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 25th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 23rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.